Results 221 to 230 of about 94,924 (312)

Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Anaplastic lymphoma kinase (ALK) inhibitors have markedly improved outcomes in ALK‐positive nonsmall‐cell lung cancer (NSCLC). While their efficacy is well documented, rare or organ‐specific toxicities remain underreported, limiting clinicians' ability to anticipate and manage adverse events during treatment or rechallenge with tyrosine kinase
Kang Xie, Nie Xu
wiley   +1 more source

Understanding Biologics in CRSwNP: Related Events and Insights. [PDF]

open access: yesCurr Allergy Asthma Rep
Izquierdo-Domínguez A   +4 more
europepmc   +1 more source

Trimethoprim/Sulfamethoxazole‐Induced Systemic Toxic Epidermal Necrolysis Syndrome: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Trimethoprim/sulfamethoxazole can induce life‐threatening toxic epidermal necrolysis. Early recognition, immediate drug cessation, and multidisciplinary supportive care are critical. Even with aggressive therapy, mortality remains high, and SCORTEN score aids in prognostication.
Qing Wang, Litong Chen, Wen Ye
wiley   +1 more source

Incidental Detection of Asymptomatic Colonic Anisakiasis During Surveillance Colonoscopy: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Anisakiasis is a parasitic infection caused by ingestion of raw or undercooked seafood containing Anisakis larvae. Although gastric involvement is common, colonic anisakiasis is rare and may be asymptomatic, making diagnosis difficult without endoscopic evaluation.
Masashi Omori   +9 more
wiley   +1 more source

Apolipoprotein A‐I (CSL112) and Cardiovascular Outcomes in Atherosclerotic Cardiovascular Disease: A Scoping Review

open access: yesClinical Cardiology, Volume 49, Issue 5, May 2026.
Apolipoprotein A‐I (ApoA‐I), the principal protein of HDL, plays a key role in reverse cholesterol transport, inflammation modulation, and plaque stabilization in atherosclerotic cardiovascular disease. Emerging ApoA‐I–based therapies, including CSL112, enhance cholesterol efflux capacity, though definitive reductions in cardiovascular events remain ...
Awais Habib   +6 more
wiley   +1 more source

Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

open access: yesJPGN Reports, Volume 7, Issue 2, Page 185-191, May 2026.
Abstract Objectives Eosinophilic esophagitis (EoE) is a type 2 cytokine‐mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL‐4 and IL‐13 signaling, which are key inflammatory mediators in EoE and other allergic disorders.
Sindhura Kasturi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy